<- Go Home
Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Market Cap
$644.1M
Volume
619.0K
Cash and Equivalents
$67.9M
EBITDA
-$27.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$188.5M
Profit Margin
68.41%
52 Week High
$17.82
52 Week Low
$8.67
Dividend
N/A
Price / Book Value
-97.49
Price / Earnings
-11.24
Price / Tangible Book Value
-8.34
Enterprise Value
$706.4M
Enterprise Value / EBITDA
-27.56
Operating Income
-$32.9M
Return on Equity
949.46%
Return on Assets
-9.36
Cash and Short Term Investments
$67.9M
Debt
$130.2M
Equity
-$6.6M
Revenue
$275.5M
Unlevered FCF
$968.0K
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium